Successful use of maintenance infliximab for nephropathy in a patient with secondary amyloidosis complicating Crohn's disease

10Citations
Citations of this article
28Readers
Mendeley users who have this article in their library.

Abstract

Systemic AA amyloidosis is a complication of various inflammatory diseases including Crohn's disease (CD). Amyloid nephropathy is the most common clinical presentation of AA amyloidosis leading to renal failure, and affected patients often require hemodialysis and ultimately renal transplantation. We herein report the successful use of infliximab as maintenance therapy for amyloid nephropathy in a patient with CD. In the present patient, surgical treatment and infliximab infusion immediately induced a remission of CD, and scheduled infliximab therapy successfully maintained the patient's stable condition for three years, with a significant decrease in the serum creatinine level. © 2013 The Japanese Society of Internal Medicine.

Cite

CITATION STYLE

APA

Tada, Y., Ishihara, S., Ito, T., Matsui, K., Sonoyama, H., Oka, A., … Kinoshita, Y. (2013). Successful use of maintenance infliximab for nephropathy in a patient with secondary amyloidosis complicating Crohn’s disease. Internal Medicine, 52(17), 1899–1902. https://doi.org/10.2169/internalmedicine.52.0340

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free